DexCom, Inc. DXCM

Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.

MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

MILAN, September 28, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...

DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...

DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.

Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- "Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.

SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.